IDNA vs. CNCR

Last updated Jun 3, 2026

IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. IDNA charges 0.47%/yr vs 0.79%/yr for CNCR.

Performance

IDNA vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IDNA

• 1D: -2.18%
• 1M: -2.18%
• YTD: 9.51%
• 6M: 10.53%
• 1Y: 41.74%
• 3Y*: 6.48%
• 5Y*: -8.26%
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IDNA vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	-1.10%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

IDNA vs. CNCR - Sectors Allocation Comparison

Sectors	IDNA	CNCR
Healthcare	97.8%	96.6%
Industrials	0.4%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IDNA vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA

IDNA Risk / Return Rank: 57
IDNA Sharpe Ratio Rank: 49
IDNA Sortino Ratio Rank: 50
IDNA Omega Ratio Rank: 43
IDNA Calmar Ratio Rank: 79
IDNA Martin Ratio Rank: 64

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDNA vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IDNA	CNCR	Difference
Sharpe ratio Return per unit of total volatility	1.71	—	—
Sortino ratio Return per unit of downside risk	2.48	—	—
Omega ratio Gain probability vs. loss probability	1.28	—	—
Calmar ratio Return relative to maximum drawdown	4.09	—	—
Martin ratio Return relative to average drawdown	11.79	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IDNA	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.71	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.10	—	—

Drawdowns

IDNA vs. CNCR - Drawdown Comparison

The maximum IDNA drawdown since its inception was -68.26%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IDNA and CNCR.

Drawdown Indicators

	IDNA	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-68.26%	0.00%	-68.26%
Max Drawdown (1Y) Largest decline over 1 year	-10.66%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-29.73%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-68.26%	—	—
Current Drawdown Current decline from peak	-46.01%	0.00%	-46.01%
Average Drawdown Average peak-to-trough decline	-36.24%	0.00%	-36.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.70%	—	—

Volatility

Volatility by Period

	IDNA	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.24%	—	—
Volatility (6M) Calculated over the trailing 6-month period	18.21%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	24.51%	0.00%	+24.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.42%	0.00%	+28.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	29.53%	0.00%	+29.53%

IDNA vs. CNCR - Expense Ratio Comparison

IDNA has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

IDNA vs. CNCR - Dividend Comparison

IDNA's dividend yield for the trailing twelve months is around 1.08%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	1.08%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Frequently Asked Questions

Which ETF is better, IDNA or CNCR?

On fees, IDNA is cheaper at 0.47% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, IDNA or CNCR?

IDNA is cheaper with a 0.47% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, IDNA or CNCR?

IDNA has the higher dividend yield at 1.08%, compared with 0.00% for CNCR.

What is the main difference between IDNA and CNCR?

IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: iShares and Exchange Traded Concepts. Their fees differ too: 0.47% for IDNA and 0.79% for CNCR.